RxDoctor Payments Data

Phillip Ham, DO

Family Medicine · Pensacola, FLNPI 1417960162

Payments from drug & device makers

$9,536in general payments, 2019–2025

Across 579 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$781
  • GSK$759
  • AstraZeneca$717
  • Boehringer Ingelheim$714
  • Pfizer$620
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$9,37698%
  • Education$1602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,536 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$43,053
Medicare patients
191
Services billed
1,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide67$117,232
JardianceEmpagliflozin64$73,564
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$38,799
TrulicityDulaglutide14$37,202
LinzessLinaclotide26$35,882
EliquisApixaban36$34,496
OzempicSemaglutide11$17,806
MyrbetriqMirabegron22$17,423
JanuviaSitagliptin Phosphate11$14,788
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,622
XareltoRivaroxaban16$10,305
Albuterol Sulfate HfaAlbuterol Sulfate129$5,481
Duloxetine Hcl77$3,327
Rosuvastatin Calcium209$3,227
Atorvastatin Calcium317$2,646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$781$154,43481 claims
Boehringer IngelheimJardiance$714$73,56464 claims
GSKTrelegy Ellipta$759$38,79934 claims
AbbVieLinzess, Synthroid$562$36,70146 claims
PfizerEliquis$620$34,49636 claims
Novo NordiskOzempic$1,392$17,80611 claims
Astellas Pharma US IncMyrbetriq$244$17,42322 claims
MerckJanuvia$204$14,78811 claims
AstraZenecaBreztri Aerosphere$717$10,62214 claims
Johnson & JohnsonXarelto$530$10,30516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →